Status:
COMPLETED
Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Schizophrenia
Eligibility:
MALE
18-50 years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to determine whether a short-term administration of an investigational study drug may provide evidence of improvement in cognitive functioning in a group of stabl...
Detailed Description
The goal of this study is to determine whether the short-term (4 week), double-blind administration of Merck L-830982 provides evidence of improvement in cognitive functioning in stable male subjects ...
Eligibility Criteria
Inclusion
- Male participants
- Between the ages of 18 and 50
- Meet diagnostic criteria for schizophrenia or schizoaffective disorder
- Are clinically stable for a minimum of 3 months on current dose of medication
- Are unemployed (i.e., work less than 20 hours per week at competitive employment)
Exclusion
- Psychoactive substance dependence within the past 6 months or substance abuse within the past month
- History of head trauma or other neurological disorder
- Medical illness or medications, such as benzodiazepine treatment or HIV medications, that may be affected by study participation (the study doctor will discuss this with potential subjects)
- Mental retardation
- Seizure disorder
- History of a heart attack, arrhythmia, or other heart disease
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00129441
Start Date
August 1 2005
End Date
January 1 2008
Last Update
October 17 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213